BMY Bristol-Myers Squibb Company

-1.52  -3%
Previous Close 53.64
Open 53.21
Price To Book 6.23
Market Cap 85070200101
Shares 1,632,198,774
Volume 9,995,147
Short Ratio 1.44
Av. Daily Volume 9,566,125

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 primary completion date 1H 2021.
CM-649 – Opdivo+ Yervoy or Chemo
Gastric cancer
Phase 3 data due 1Q 2020.
CM-714 Opdivo + Yervoy
First-line Head and Neck Cancer
Phase 1/2 data at SITC November 2018 noted ORR 53%.
NKTR-214 + OPDIVO (nivolumab) - PIVOT-02
Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers
Late-breaker at SITC November 11, 2017. ORR 14-32%.
BMS-986205 and Nivolumab
Advanced tumors
Phase 2 ongoing. Abstract presented at ASCO June 2018.
Opdivo and Rubraca
Castration-resistant prostate cancer (mCRPC)
Phase 3 trial planned.
Opdivo and Rubraca
Triple-negative breast cancers
Phase 3 enrollment has commenced - noted August 8, 2018.
Opdivo and Rubraca ATHENA
Ovarian Cancer - First-line maintenance treatment
Approval announced March 6, 2018.
Opdivo - 4 week applications
Approval announced November 10, 2017.
Sprycel (dasatinib)
Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia
Approval announced July 6, 2017.
Psoriatic Arthritis (PsA)
Phase 1/2 preliminary data presented at ASCO June 2, 2017. ORR=21%.
CM-358 – Opdivo
Cervical, vaginal and vulvar cancers
Phase 1/2 ORR rate of 12.5% noted at ASCO June 3, 2017.
BMS-986016 - LAG-3 + Opdivo
Phase 3 trial initiated mid-2017. Data from Phase 1/2 at ASH 2017 showed a 83% ORR and 62% CR.
ADCETRIS and Opdivo CM-812
Relapsed Hodgkin Lymphoma
Approved under priority review September 22, 2017.
Opdivo (CM-040)
Previously Treated Hepatocellular Carcinoma
Phase 2 data due 2018.
TG4010 and Opdivo
Non-squamous non-small cell lung cancer (NSCLC)
Phase 2 late breaker at ASCO June 5, 2017. Control rate 44%. ORR 19%.
Opdivo + Yervoy
Malignant pleural mesothelioma (MPM)
Phase 1/2 initiated April 2017.
Epacadostat with Opdivo (nivolumab) - (ECHO-207)
Solid tumors
Phase 1/2 trial enrolling. Oral presentation at ASCO June 5, 2017.
Epacadostat with Opdivo (nivolumab) - (ECHO-204)
Solid tumors
Approval announced August 1, 2017.
CM-142 – Opdivo
(dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC)
Phase 3 first overall survival (OS) positive data released April 3, 2017
CM - 067 Opdivo in combination with Yervoy
Phase 3 trial initiation announced July 10, 2017.
CABOMETYX (cabozantinib) with Opdivo and Yervoy - CheckMate 9ER
First-line renal cell carcinoma
Phase 3 data released January 19, 2017.
Opdivo - ONO-4538-12
Gastric cancer
Phase 2 presentation at AACR Meeting April 16, 2018.
CM-568 - Opdivo + Yervoy
First-line Non-small cell lung cancer (NSCLC)
Phase 3 data due 2020.
CM-651 – Opdivo + Yervoy
First-line Head and Neck Cancer
Phase 3 data due 1H 2019.
CM-459 – Opdivo
First-line Hepatocellular carcinoma (HCC) - cancer
Phase 3 ongoing.
CM-511 – Opdivo + Yervoy
First-line Melanoma
Phase 3 trial did not meet primary endpoint - November 26, 2018.
CM-451 – Opdivo + Yervoy
First-line Small cell lung cancer (SCLC)
Phase 3 data released October 12, 2018 - primary endpoint not met.
CM-331– Opdivo
Second-line Small cell lung cancer (SCLC)
Phase 3 interim data released June 6, 2017 - primary endpoint met. Data presented at ESMO September 10, 2017 - HR 0.65 compared to Yervoy. FDA Approval announced December 20, 2017.
CM-238 – Opdivo (Adjuvant)
Approved April 16, 2018.
CM-214 – Opdivo + Yervoy
First-line Renal cell carcinoma (RCC)
PDUFA date for sBLA extended by three months to May 20, 2019.
CM-227 – Opdivo + Yervoy
First-line Non-small cell lung cancer (NSCLC)
Phase 3 data released April 3, 2017 - primary endpoint not met.
CM-143 – Opdivo
Second-line Glioblastoma (GBM) cancer
Phase 3 trial met primary endpoint - November 30, 2017.
CM-078 – Opdivo
Second-line Non-small cell lung cancer (NSCLC)
Urothelial Carcinoma - Bladder cancer
Opdivo (nivolumab)
Bladder cancer
Approval announced July 11, 2018.
CM-142 – Opdivo
(dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC)
FDA approval announced August 17, 2018.
CM-32 - Opdivo+chemo
Small cell lung cancer (SCLC)
Phase 3 clinical hold lifted June 1, 2018.
CM-602 – Opdivo + pomalidomide and dexamethasone
Multiple Myeloma
FDA approval announced November 6, 2018.
Empliciti (elotuzumab) - ELOQUENT-3
Relapsed/refractory multiple myeloma
PDUFA date for sBLA December 29, 2018.
Sprycel (dasatinib)
Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Phase 2 trial to be initiated 1H 2019.
IPI-549 + Nivolumab (MARIO-275)
Urothelial cancer

Latest News

  1. Your first trade for Friday, December 14
  2. Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus
  3. featured highlights include: Nexstar Media, Bristol-Myers Squibb, Capital One Financial, Helmerich & Payne and Progressive
  4. Today's Research Reports on Trending Tickers: Bristol-Myers Squibb and Novartis
  5. Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know
  6. J&J's Tremfya Beats Novartis' Cosentyx in Head-to-Head Study
  7. Mallinckrodt's Roxicodone Reformulation Gets CRL From FDA
  8. Are You Overlooking This High-Growth Industry During Corrections and Recessions?
  9. See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.
  10. Upgraded Broker Ratings Make These 5 Stocks Worth a Look Now
  11. Roche to Create Companion Diagnostic Test for Merck's Keytruda
  12. Pfizer's (PFE) Shares Drop on Rating Downgrade by JP Morgan
  13. 5 Companies That Raised Dividends as Bond Yields Increase
  14. Bristol-Myers to Study Opdivo in Combo With Vedanta's VE800
  15. Roche's Tecentriq Gets FDA Approval for First-Line NSCLC
  16. Today's Research Reports on Trending Tickers: Johnson & Johnson and Bristol-Myers Squibb
  17. Bristol-Myers Squibb and Vedanta Biosciences Announce a New Clinical Collaboration to Evaluate OPDIVO (Nivolumab) and VE800 in Patients with Advanced or Metastatic Cancers
  18. Is Bristol Myers Squibb Co. (BMY) A Good Stock To Buy According To Hedge Funds?
  19. Could These Be the Next 2 Biotech Buyouts?